View Future GrowthSeoulin BioscienceLtd 過去の業績過去 基準チェック /06Seoulin BioscienceLtdの収益は年間平均-41.2%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間17.5% 0.7%割合で 減少しています。 Seoulin BioscienceLtdの自己資本利益率は0.7%であり、純利益率は0.9%です。主要情報-41.18%収益成長率-40.94%EPS成長率Biotechs 業界の成長11.70%収益成長率-0.72%株主資本利益率0.67%ネット・マージン0.95%前回の決算情報31 Dec 2025最近の業績更新分析記事 • Nov 26Solid Earnings May Not Tell The Whole Story For Seoulin BioscienceLtd (KOSDAQ:038070)Seoulin Bioscience Co.,Ltd.'s ( KOSDAQ:038070 ) robust recent earnings didn't do much to move the stock. We think this...分析記事 • Mar 25Concerns Surrounding Seoulin BioscienceLtd's (KOSDAQ:038070) PerformanceThe market shrugged off Seoulin Bioscience Co.,Ltd.'s ( KOSDAQ:038070 ) solid earnings report. We think that investors...Reported Earnings • May 19First quarter 2024 earnings released: EPS: ₩66.00 (vs ₩211 in 1Q 2023)First quarter 2024 results: EPS: ₩66.00 (down from ₩211 in 1Q 2023). Revenue: ₩18.9b (down 17% from 1Q 2023). Net income: ₩564.6m (down 69% from 1Q 2023). Profit margin: 3.0% (down from 8.0% in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has only fallen by 24% per year, which means it has not declined as severely as earnings.Reported Earnings • Nov 19Third quarter 2023 earnings released: EPS: ₩67.00 (vs ₩144 in 3Q 2022)Third quarter 2023 results: EPS: ₩67.00 (down from ₩144 in 3Q 2022). Revenue: ₩19.6b (down 12% from 3Q 2022). Net income: ₩563.1m (down 53% from 3Q 2022). Profit margin: 2.9% (down from 5.4% in 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 12% per year, which means it is performing significantly worse than earnings.Reported Earnings • Mar 19Full year 2022 earnings released: EPS: ₩1,163 (vs ₩1,918 in FY 2021)Full year 2022 results: EPS: ₩1,163 (down from ₩1,918 in FY 2021). Revenue: ₩102.4b (up 27% from FY 2021). Net income: ₩9.51b (down 39% from FY 2021). Profit margin: 9.3% (down from 20% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 30% per year whereas the company’s share price has increased by 28% per year.Reported Earnings • Mar 13Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: EPS: ₩1,952 (up from ₩612 in FY 2020). Revenue: ₩80.7b (up 24% from FY 2020). Net income: ₩15.6b (up 219% from FY 2020). Profit margin: 19% (up from 7.5% in FY 2020). Revenue exceeded analyst estimates by 3.7%. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.すべての更新を表示Recent updatesNew Risk • Mar 20New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 0.9% Last year net profit margin: 3.9% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 41% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.9% net profit margin). Market cap is less than US$100m (₩57.2b market cap, or US$38.2m).お知らせ • Mar 07Seoulin Bioscience Co.,Ltd., Annual General Meeting, Mar 26, 2026Seoulin Bioscience Co.,Ltd., Annual General Meeting, Mar 26, 2026, at 09:00 Tokyo Standard Time. Location: auditorium, 593-16, dongtangiheung-ro, gyeonggi-do, hwaseong South KoreaUpcoming Dividend • Dec 22Upcoming dividend of ₩97.68 per shareEligible shareholders must have bought the stock before 29 December 2025. Payment date: 20 April 2026. Payout ratio is a comfortable 40% but the company is paying out more than the cash it is generating. Trailing yield: 1.4%. Lower than top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (0.6%).分析記事 • Nov 26Solid Earnings May Not Tell The Whole Story For Seoulin BioscienceLtd (KOSDAQ:038070)Seoulin Bioscience Co.,Ltd.'s ( KOSDAQ:038070 ) robust recent earnings didn't do much to move the stock. We think this...Declared Dividend • Nov 13Dividend of ₩97.68 announcedShareholders will receive a dividend of ₩97.68. Ex-date: 29th December 2025 Payment date: 20th April 2026 Dividend yield will be 1.4%, which is higher than the industry average of 0.5%. Sustainability & Growth Dividend is covered by earnings (46% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 3.0% per year over the past 6 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to decline by 49% to shift the payout ratio to a potentially unsustainable range, which is more than the 14% EPS decline seen over the last 5 years.お知らせ • Nov 12Seoulin Bioscience Co.,Ltd. announces Annual dividend, payable on April 20, 2026Seoulin Bioscience Co.,Ltd. announced Annual dividend of KRW 97.6848 per share payable on April 20, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.New Risk • May 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 25% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (₩72.5b market cap, or US$52.7m).分析記事 • Mar 25Concerns Surrounding Seoulin BioscienceLtd's (KOSDAQ:038070) PerformanceThe market shrugged off Seoulin Bioscience Co.,Ltd.'s ( KOSDAQ:038070 ) solid earnings report. We think that investors...New Risk • Mar 25New major risk - Dividend sustainabilityThe dividend is not well covered by earnings and cash flows. The company is paying a dividend despite being loss-making. The company is paying a dividend despite having no free cash flows. Dividend yield: 1.5% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 22% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩55.8b market cap, or US$38.0m).New Risk • Mar 03New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 19% per year over the past 5 years. Minor Risks Paying a dividend despite being loss-making. Market cap is less than US$100m (₩60.1b market cap, or US$41.2m).お知らせ • Feb 21Seoulin Bioscience Co.,Ltd., Annual General Meeting, Mar 26, 2025Seoulin Bioscience Co.,Ltd., Annual General Meeting, Mar 26, 2025, at 09:00 Tokyo Standard Time. Location: auditorium, 593-16, dongtangiheung-ro, gyeonggi-do, hwaseong South KoreaUpcoming Dividend • Dec 20Upcoming dividend of ₩97.66 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 28 April 2025. The company is not currently making a profit but it is cash flow positive. Trailing yield: 1.4%. Lower than top quartile of South Korean dividend payers (3.9%). Higher than average of industry peers (0.5%).分析記事 • Dec 04Seoulin Bioscience Co.,Ltd.'s (KOSDAQ:038070) Low P/S No Reason For ExcitementWith a price-to-sales (or "P/S") ratio of 0.9x Seoulin Bioscience Co.,Ltd. ( KOSDAQ:038070 ) may be sending very...New Risk • Dec 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 19% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$100m (₩70.3b market cap, or US$49.6m).お知らせ • Aug 08Seoulin Bioscience Co.,Ltd. (KOSDAQ:A038070) announces an Equity Buyback for KRW 1,000 million worth of its shares.Seoulin Bioscience Co.,Ltd. (KOSDAQ:A038070) announces a share repurchase program. Under the program, the company will repurchase up to KRW 1,000 million worth of its shares pursuant to a contract with Daishin Securities Co., Ltd. The purpose of the program is to improve shareholder value and to stabilize stock price. The program will expire on February 6, 2025. As of August 6, 2024, the company had 293,246 shares in treasury within scope available for dividend and 55,397 shares in treasury through other repurchase.Reported Earnings • May 19First quarter 2024 earnings released: EPS: ₩66.00 (vs ₩211 in 1Q 2023)First quarter 2024 results: EPS: ₩66.00 (down from ₩211 in 1Q 2023). Revenue: ₩18.9b (down 17% from 1Q 2023). Net income: ₩564.6m (down 69% from 1Q 2023). Profit margin: 3.0% (down from 8.0% in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has only fallen by 24% per year, which means it has not declined as severely as earnings.Upcoming Dividend • Dec 20Upcoming dividend of ₩127 per share at 1.4% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 22 April 2024. Payout ratio is a comfortable 40% but the company is not cash flow positive. Trailing yield: 1.4%. Lower than top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (0.7%).Reported Earnings • Nov 19Third quarter 2023 earnings released: EPS: ₩67.00 (vs ₩144 in 3Q 2022)Third quarter 2023 results: EPS: ₩67.00 (down from ₩144 in 3Q 2022). Revenue: ₩19.6b (down 12% from 3Q 2022). Net income: ₩563.1m (down 53% from 3Q 2022). Profit margin: 2.9% (down from 5.4% in 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 12% per year, which means it is performing significantly worse than earnings.Reported Earnings • Mar 19Full year 2022 earnings released: EPS: ₩1,163 (vs ₩1,918 in FY 2021)Full year 2022 results: EPS: ₩1,163 (down from ₩1,918 in FY 2021). Revenue: ₩102.4b (up 27% from FY 2021). Net income: ₩9.51b (down 39% from FY 2021). Profit margin: 9.3% (down from 20% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 30% per year whereas the company’s share price has increased by 28% per year.Upcoming Dividend • Dec 21Upcoming dividend of ₩97.56 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 17 April 2023. Payout ratio is a comfortable 9.4% and this is well supported by cash flows. Trailing yield: 0.8%. Lower than top quartile of South Korean dividend payers (3.3%). In line with average of industry peers (0.7%).Valuation Update With 7 Day Price Move • Dec 15Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩14,100, the stock trades at a trailing P/E ratio of 13.3x. Average trailing P/E is 25x in the Biotechs industry in South Korea. Total returns to shareholders of 80% over the past three years.Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Aug 02Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩18,400, the stock trades at a trailing P/E ratio of 9.3x. Average trailing P/E is 26x in the Biotechs industry in South Korea. Total returns to shareholders of 206% over the past three years.Valuation Update With 7 Day Price Move • Jul 11Investor sentiment improved over the past weekAfter last week's 42% share price gain to ₩15,900, the stock trades at a trailing P/E ratio of 8x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total returns to shareholders of 93% over the past three years.Valuation Update With 7 Day Price Move • Jun 14Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₩12,650, the stock trades at a trailing P/E ratio of 6.4x. Average trailing P/E is 25x in the Biotechs industry in South Korea. Total returns to shareholders of 50% over the past three years.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Mar 13Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: EPS: ₩1,952 (up from ₩612 in FY 2020). Revenue: ₩80.7b (up 24% from FY 2020). Net income: ₩15.6b (up 219% from FY 2020). Profit margin: 19% (up from 7.5% in FY 2020). Revenue exceeded analyst estimates by 3.7%. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Jan 27Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₩15,200, the stock trades at a trailing P/E ratio of 7x. Average trailing P/E is 33x in the Biotechs industry in South Korea. Total returns to shareholders of 67% over the past three years.Upcoming Dividend • Dec 22Upcoming dividend of ₩96.25 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 25 April 2022. Payout ratio is a comfortable 4.5% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of South Korean dividend payers (2.4%). Lower than average of industry peers (0.8%).Valuation Update With 7 Day Price Move • Nov 29Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩23,500, the stock trades at a trailing P/E ratio of 10.6x. Average trailing P/E is 34x in the Biotechs industry in South Korea. Total returns to shareholders of 178% over the past three years.Valuation Update With 7 Day Price Move • Oct 05Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₩25,650, the stock trades at a trailing P/E ratio of 34.5x. Average trailing P/E is 40x in the Biotechs industry in South Korea. Total returns to shareholders of 180% over the past three years.Valuation Update With 7 Day Price Move • Sep 14Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₩31,700, the stock trades at a trailing P/E ratio of 47x. Average trailing P/E is 42x in the Biotechs industry in South Korea. Total returns to shareholders of 237% over the past three years.Valuation Update With 7 Day Price Move • Aug 21Investor sentiment improved over the past weekAfter last week's 38% share price gain to ₩37,800, the stock trades at a trailing P/E ratio of 56.1x. Average trailing P/E is 45x in the Biotechs industry in South Korea. Total returns to shareholders of 310% over the past three years.Valuation Update With 7 Day Price Move • Aug 06Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩25,000, the stock trades at a trailing P/E ratio of 37.1x. Average trailing P/E is 46x in the Biotechs industry in South Korea. Total returns to shareholders of 172% over the past three years.Valuation Update With 7 Day Price Move • Jul 06Investor sentiment improved over the past weekAfter last week's 25% share price gain to ₩27,250, the stock trades at a trailing P/E ratio of 40.4x. Average trailing P/E is 49x in the Biotechs industry in South Korea. Total returns to shareholders of 186% over the past three years.Valuation Update With 7 Day Price Move • Jun 21Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩21,900, the stock trades at a trailing P/E ratio of 32.5x. Average trailing P/E is 42x in the Biotechs industry in South Korea. Total returns to shareholders of 129% over the past three years.Valuation Update With 7 Day Price Move • May 13Investor sentiment improved over the past weekAfter last week's 37% share price gain to ₩19,650, the stock trades at a trailing P/E ratio of 32.1x. Average trailing P/E is 51x in the Biotechs industry in South Korea. Total returns to shareholders of 90% over the past three years.分析記事 • May 03Seoulin Bioscience Co.,Ltd. (KOSDAQ:038070) Is An Attractive Dividend Stock - Here's WhyDividend paying stocks like Seoulin Bioscience Co.,Ltd. ( KOSDAQ:038070 ) tend to be popular with investors, and for...Reported Earnings • Mar 19Full year 2020 earnings released: EPS ₩636 (vs ₩1,143 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: ₩65.1b (up 20% from FY 2019). Net income: ₩4.89b (down 45% from FY 2019). Profit margin: 7.5% (down from 16% in FY 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.分析記事 • Mar 13Should Weakness in Seoulin Bioscience Co.,Ltd.'s (KOSDAQ:038070) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?Seoulin BioscienceLtd (KOSDAQ:038070) has had a rough three months with its share price down 8.8%. However, the...Is New 90 Day High Low • Mar 09New 90-day low: ₩12,000The company is down 12% from its price of ₩13,667 on 09 December 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 14% over the same period.分析記事 • Feb 15Introducing Seoulin BioscienceLtd (KOSDAQ:038070), A Stock That Climbed 54% In The Last YearSeoulin Bioscience Co.,Ltd. ( KOSDAQ:038070 ) shareholders might be concerned after seeing the share price drop 11% in...分析記事 • Jan 20Is Seoulin Bioscience Co.,Ltd. (KOSDAQ:038070) A Great Dividend Stock?Today we'll take a closer look at Seoulin Bioscience Co.,Ltd. ( KOSDAQ:038070 ) from a dividend investor's perspective...Valuation Update With 7 Day Price Move • Jan 13Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₩14,900, the stock is trading at a trailing P/E ratio of 28.1x, down from the previous P/E ratio of 33.6x. This compares to an average P/E of 57x in the Biotechs industry in South Korea. Total returns to shareholders over the past three years are 40%.Valuation Update With 7 Day Price Move • Jan 06Investor sentiment improved over the past weekAfter last week's 33% share price gain to ₩17,850, the stock is trading at a trailing P/E ratio of 33.6x, up from the previous P/E ratio of 25.3x. This compares to an average P/E of 58x in the Biotechs industry in South Korea. Total returns to shareholders over the past three years are 76%.Is New 90 Day High Low • Jan 06New 90-day high: ₩17,850The company is up 48% from its price of ₩12,031 on 08 October 2020. The South Korean market is up 24% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 23% over the same period.分析記事 • Dec 25Three Days Left Until Seoulin Bioscience Co.,Ltd. (KOSDAQ:038070) Trades Ex-DividendSome investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...Upcoming Dividend • Dec 22Upcoming Dividend of ₩93.52 Per ShareWill be paid on the 17th of April to those who are registered shareholders by the 29th of December. The trailing yield of 0.7% is below the top quartile of South Korean dividend payers (2.6%), but it is higher than industry peers (0.3%).Is New 90 Day High Low • Dec 14New 90-day high: ₩14,650The company is up 3.0% from its price of ₩14,250 on 15 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 6.0% over the same period.分析記事 • Dec 06Is Seoulin Bioscience Co.,Ltd.'s (KOSDAQ:038070) Recent Stock Performance Influenced By Its Fundamentals In Any Way?Seoulin BioscienceLtd (KOSDAQ:038070) has had a great run on the share market with its stock up by a significant 10...Valuation Update With 7 Day Price Move • Nov 10Market bids up stock over the past weekAfter last week's 17% share price gain to ₩13,750, the stock is trading at a trailing P/E ratio of 26.1x, up from the previous P/E ratio of 22.3x. This compares to an average P/E of 66x in the Biotechs industry in South Korea. Total returns to shareholders over the past three years are 28%.Is New 90 Day High Low • Oct 23New 90-day low: ₩11,250The company is down 11% from its price of ₩12,700 on 24 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Biotechs industry, which is also down 11% over the same period.収支内訳Seoulin BioscienceLtd の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史KOSDAQ:A038070 収益、費用、利益 ( )KRW Millions日付収益収益G+A経費研究開発費31 Dec 2577,09173214,09693530 Sep 2576,7382,12114,6421,24730 Jun 2571,0001,84614,0201,33131 Mar 2574,5722,72615,3441,37831 Dec 2475,4102,91415,0251,21430 Sep 2482,093-66214,50796130 Jun 2484,514-59114,71381831 Mar 2485,821-1,35714,35073831 Dec 2389,569-11814,95478530 Sep 2383,8783,30714,27689030 Jun 2386,5383,94514,31190631 Mar 23100,6379,86913,35190431 Dec 22104,70810,12912,92887030 Sep 22103,5708,76512,98375330 Jun 22103,58620,65012,46074231 Mar 2289,47516,31512,07175531 Dec 2180,53915,70011,17278730 Sep 2180,21917,67010,19980930 Jun 2175,1055,8909,85091531 Mar 2167,6895,3539,60397031 Dec 2065,0854,8939,52299830 Sep 2062,5204,2519,7881,07730 Jun 2058,3494,0689,78495531 Mar 2057,0429,4379,98998531 Dec 1954,4108,8849,86195530 Sep 1950,7568,59010,1721,13530 Jun 1951,7008,34610,2701,18431 Mar 1951,2312,64010,1131,18331 Dec 1849,8772,62510,0281,19030 Sep 1847,4442,3149,9731,12630 Jun 1843,5121,7149,6481,08531 Mar 1842,3171,5409,65998331 Dec 1742,6192,0619,49599830 Sep 1744,4373,0088,77485730 Jun 1744,9373,0079,27267931 Mar 1746,6984,7109,26666831 Dec 1644,8894,0738,76879530 Sep 1644,3143,5999,03366130 Jun 1643,4813,2308,91566131 Mar 1642,0441,7728,36864431 Dec 1541,6281,8258,24256630 Sep 1541,5381,9527,87159130 Jun 1539,6822,2577,769591質の高い収益: A038070には₩795.0M } という大きな 一回限りの 損失があり、過去 12 か月の財務実績が31st December, 2025に影響を及ぼしています。利益率の向上: A038070の現在の純利益率 (0.9%)は、昨年(3.9%)よりも低くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: A038070の収益は過去 5 年間で年間41.2%減少しました。成長の加速: A038070は過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。収益対業界: A038070は過去 1 年間で収益成長率がマイナス ( -74.9% ) となったため、 Biotechs業界平均 ( 25.4% ) と比較することが困難です。株主資本利益率高いROE: A038070の 自己資本利益率 ( 0.7% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/23 19:04終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Seoulin Bioscience Co.,Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Sung Hwan ChoiKyobo Securities Co., LtdJu-Hong ChoeLS Securities Co., Ltd.Seung KimSK Securities Co., Ltd.1 その他のアナリストを表示
分析記事 • Nov 26Solid Earnings May Not Tell The Whole Story For Seoulin BioscienceLtd (KOSDAQ:038070)Seoulin Bioscience Co.,Ltd.'s ( KOSDAQ:038070 ) robust recent earnings didn't do much to move the stock. We think this...
分析記事 • Mar 25Concerns Surrounding Seoulin BioscienceLtd's (KOSDAQ:038070) PerformanceThe market shrugged off Seoulin Bioscience Co.,Ltd.'s ( KOSDAQ:038070 ) solid earnings report. We think that investors...
Reported Earnings • May 19First quarter 2024 earnings released: EPS: ₩66.00 (vs ₩211 in 1Q 2023)First quarter 2024 results: EPS: ₩66.00 (down from ₩211 in 1Q 2023). Revenue: ₩18.9b (down 17% from 1Q 2023). Net income: ₩564.6m (down 69% from 1Q 2023). Profit margin: 3.0% (down from 8.0% in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has only fallen by 24% per year, which means it has not declined as severely as earnings.
Reported Earnings • Nov 19Third quarter 2023 earnings released: EPS: ₩67.00 (vs ₩144 in 3Q 2022)Third quarter 2023 results: EPS: ₩67.00 (down from ₩144 in 3Q 2022). Revenue: ₩19.6b (down 12% from 3Q 2022). Net income: ₩563.1m (down 53% from 3Q 2022). Profit margin: 2.9% (down from 5.4% in 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 12% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Mar 19Full year 2022 earnings released: EPS: ₩1,163 (vs ₩1,918 in FY 2021)Full year 2022 results: EPS: ₩1,163 (down from ₩1,918 in FY 2021). Revenue: ₩102.4b (up 27% from FY 2021). Net income: ₩9.51b (down 39% from FY 2021). Profit margin: 9.3% (down from 20% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 30% per year whereas the company’s share price has increased by 28% per year.
Reported Earnings • Mar 13Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: EPS: ₩1,952 (up from ₩612 in FY 2020). Revenue: ₩80.7b (up 24% from FY 2020). Net income: ₩15.6b (up 219% from FY 2020). Profit margin: 19% (up from 7.5% in FY 2020). Revenue exceeded analyst estimates by 3.7%. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.
New Risk • Mar 20New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 0.9% Last year net profit margin: 3.9% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 41% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.9% net profit margin). Market cap is less than US$100m (₩57.2b market cap, or US$38.2m).
お知らせ • Mar 07Seoulin Bioscience Co.,Ltd., Annual General Meeting, Mar 26, 2026Seoulin Bioscience Co.,Ltd., Annual General Meeting, Mar 26, 2026, at 09:00 Tokyo Standard Time. Location: auditorium, 593-16, dongtangiheung-ro, gyeonggi-do, hwaseong South Korea
Upcoming Dividend • Dec 22Upcoming dividend of ₩97.68 per shareEligible shareholders must have bought the stock before 29 December 2025. Payment date: 20 April 2026. Payout ratio is a comfortable 40% but the company is paying out more than the cash it is generating. Trailing yield: 1.4%. Lower than top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (0.6%).
分析記事 • Nov 26Solid Earnings May Not Tell The Whole Story For Seoulin BioscienceLtd (KOSDAQ:038070)Seoulin Bioscience Co.,Ltd.'s ( KOSDAQ:038070 ) robust recent earnings didn't do much to move the stock. We think this...
Declared Dividend • Nov 13Dividend of ₩97.68 announcedShareholders will receive a dividend of ₩97.68. Ex-date: 29th December 2025 Payment date: 20th April 2026 Dividend yield will be 1.4%, which is higher than the industry average of 0.5%. Sustainability & Growth Dividend is covered by earnings (46% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 3.0% per year over the past 6 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to decline by 49% to shift the payout ratio to a potentially unsustainable range, which is more than the 14% EPS decline seen over the last 5 years.
お知らせ • Nov 12Seoulin Bioscience Co.,Ltd. announces Annual dividend, payable on April 20, 2026Seoulin Bioscience Co.,Ltd. announced Annual dividend of KRW 97.6848 per share payable on April 20, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.
New Risk • May 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 25% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (₩72.5b market cap, or US$52.7m).
分析記事 • Mar 25Concerns Surrounding Seoulin BioscienceLtd's (KOSDAQ:038070) PerformanceThe market shrugged off Seoulin Bioscience Co.,Ltd.'s ( KOSDAQ:038070 ) solid earnings report. We think that investors...
New Risk • Mar 25New major risk - Dividend sustainabilityThe dividend is not well covered by earnings and cash flows. The company is paying a dividend despite being loss-making. The company is paying a dividend despite having no free cash flows. Dividend yield: 1.5% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 22% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩55.8b market cap, or US$38.0m).
New Risk • Mar 03New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 19% per year over the past 5 years. Minor Risks Paying a dividend despite being loss-making. Market cap is less than US$100m (₩60.1b market cap, or US$41.2m).
お知らせ • Feb 21Seoulin Bioscience Co.,Ltd., Annual General Meeting, Mar 26, 2025Seoulin Bioscience Co.,Ltd., Annual General Meeting, Mar 26, 2025, at 09:00 Tokyo Standard Time. Location: auditorium, 593-16, dongtangiheung-ro, gyeonggi-do, hwaseong South Korea
Upcoming Dividend • Dec 20Upcoming dividend of ₩97.66 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 28 April 2025. The company is not currently making a profit but it is cash flow positive. Trailing yield: 1.4%. Lower than top quartile of South Korean dividend payers (3.9%). Higher than average of industry peers (0.5%).
分析記事 • Dec 04Seoulin Bioscience Co.,Ltd.'s (KOSDAQ:038070) Low P/S No Reason For ExcitementWith a price-to-sales (or "P/S") ratio of 0.9x Seoulin Bioscience Co.,Ltd. ( KOSDAQ:038070 ) may be sending very...
New Risk • Dec 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 19% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$100m (₩70.3b market cap, or US$49.6m).
お知らせ • Aug 08Seoulin Bioscience Co.,Ltd. (KOSDAQ:A038070) announces an Equity Buyback for KRW 1,000 million worth of its shares.Seoulin Bioscience Co.,Ltd. (KOSDAQ:A038070) announces a share repurchase program. Under the program, the company will repurchase up to KRW 1,000 million worth of its shares pursuant to a contract with Daishin Securities Co., Ltd. The purpose of the program is to improve shareholder value and to stabilize stock price. The program will expire on February 6, 2025. As of August 6, 2024, the company had 293,246 shares in treasury within scope available for dividend and 55,397 shares in treasury through other repurchase.
Reported Earnings • May 19First quarter 2024 earnings released: EPS: ₩66.00 (vs ₩211 in 1Q 2023)First quarter 2024 results: EPS: ₩66.00 (down from ₩211 in 1Q 2023). Revenue: ₩18.9b (down 17% from 1Q 2023). Net income: ₩564.6m (down 69% from 1Q 2023). Profit margin: 3.0% (down from 8.0% in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has only fallen by 24% per year, which means it has not declined as severely as earnings.
Upcoming Dividend • Dec 20Upcoming dividend of ₩127 per share at 1.4% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 22 April 2024. Payout ratio is a comfortable 40% but the company is not cash flow positive. Trailing yield: 1.4%. Lower than top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (0.7%).
Reported Earnings • Nov 19Third quarter 2023 earnings released: EPS: ₩67.00 (vs ₩144 in 3Q 2022)Third quarter 2023 results: EPS: ₩67.00 (down from ₩144 in 3Q 2022). Revenue: ₩19.6b (down 12% from 3Q 2022). Net income: ₩563.1m (down 53% from 3Q 2022). Profit margin: 2.9% (down from 5.4% in 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 12% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Mar 19Full year 2022 earnings released: EPS: ₩1,163 (vs ₩1,918 in FY 2021)Full year 2022 results: EPS: ₩1,163 (down from ₩1,918 in FY 2021). Revenue: ₩102.4b (up 27% from FY 2021). Net income: ₩9.51b (down 39% from FY 2021). Profit margin: 9.3% (down from 20% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 30% per year whereas the company’s share price has increased by 28% per year.
Upcoming Dividend • Dec 21Upcoming dividend of ₩97.56 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 17 April 2023. Payout ratio is a comfortable 9.4% and this is well supported by cash flows. Trailing yield: 0.8%. Lower than top quartile of South Korean dividend payers (3.3%). In line with average of industry peers (0.7%).
Valuation Update With 7 Day Price Move • Dec 15Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩14,100, the stock trades at a trailing P/E ratio of 13.3x. Average trailing P/E is 25x in the Biotechs industry in South Korea. Total returns to shareholders of 80% over the past three years.
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Aug 02Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩18,400, the stock trades at a trailing P/E ratio of 9.3x. Average trailing P/E is 26x in the Biotechs industry in South Korea. Total returns to shareholders of 206% over the past three years.
Valuation Update With 7 Day Price Move • Jul 11Investor sentiment improved over the past weekAfter last week's 42% share price gain to ₩15,900, the stock trades at a trailing P/E ratio of 8x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total returns to shareholders of 93% over the past three years.
Valuation Update With 7 Day Price Move • Jun 14Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₩12,650, the stock trades at a trailing P/E ratio of 6.4x. Average trailing P/E is 25x in the Biotechs industry in South Korea. Total returns to shareholders of 50% over the past three years.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Mar 13Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: EPS: ₩1,952 (up from ₩612 in FY 2020). Revenue: ₩80.7b (up 24% from FY 2020). Net income: ₩15.6b (up 219% from FY 2020). Profit margin: 19% (up from 7.5% in FY 2020). Revenue exceeded analyst estimates by 3.7%. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Jan 27Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₩15,200, the stock trades at a trailing P/E ratio of 7x. Average trailing P/E is 33x in the Biotechs industry in South Korea. Total returns to shareholders of 67% over the past three years.
Upcoming Dividend • Dec 22Upcoming dividend of ₩96.25 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 25 April 2022. Payout ratio is a comfortable 4.5% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of South Korean dividend payers (2.4%). Lower than average of industry peers (0.8%).
Valuation Update With 7 Day Price Move • Nov 29Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩23,500, the stock trades at a trailing P/E ratio of 10.6x. Average trailing P/E is 34x in the Biotechs industry in South Korea. Total returns to shareholders of 178% over the past three years.
Valuation Update With 7 Day Price Move • Oct 05Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₩25,650, the stock trades at a trailing P/E ratio of 34.5x. Average trailing P/E is 40x in the Biotechs industry in South Korea. Total returns to shareholders of 180% over the past three years.
Valuation Update With 7 Day Price Move • Sep 14Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₩31,700, the stock trades at a trailing P/E ratio of 47x. Average trailing P/E is 42x in the Biotechs industry in South Korea. Total returns to shareholders of 237% over the past three years.
Valuation Update With 7 Day Price Move • Aug 21Investor sentiment improved over the past weekAfter last week's 38% share price gain to ₩37,800, the stock trades at a trailing P/E ratio of 56.1x. Average trailing P/E is 45x in the Biotechs industry in South Korea. Total returns to shareholders of 310% over the past three years.
Valuation Update With 7 Day Price Move • Aug 06Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩25,000, the stock trades at a trailing P/E ratio of 37.1x. Average trailing P/E is 46x in the Biotechs industry in South Korea. Total returns to shareholders of 172% over the past three years.
Valuation Update With 7 Day Price Move • Jul 06Investor sentiment improved over the past weekAfter last week's 25% share price gain to ₩27,250, the stock trades at a trailing P/E ratio of 40.4x. Average trailing P/E is 49x in the Biotechs industry in South Korea. Total returns to shareholders of 186% over the past three years.
Valuation Update With 7 Day Price Move • Jun 21Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩21,900, the stock trades at a trailing P/E ratio of 32.5x. Average trailing P/E is 42x in the Biotechs industry in South Korea. Total returns to shareholders of 129% over the past three years.
Valuation Update With 7 Day Price Move • May 13Investor sentiment improved over the past weekAfter last week's 37% share price gain to ₩19,650, the stock trades at a trailing P/E ratio of 32.1x. Average trailing P/E is 51x in the Biotechs industry in South Korea. Total returns to shareholders of 90% over the past three years.
分析記事 • May 03Seoulin Bioscience Co.,Ltd. (KOSDAQ:038070) Is An Attractive Dividend Stock - Here's WhyDividend paying stocks like Seoulin Bioscience Co.,Ltd. ( KOSDAQ:038070 ) tend to be popular with investors, and for...
Reported Earnings • Mar 19Full year 2020 earnings released: EPS ₩636 (vs ₩1,143 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: ₩65.1b (up 20% from FY 2019). Net income: ₩4.89b (down 45% from FY 2019). Profit margin: 7.5% (down from 16% in FY 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.
分析記事 • Mar 13Should Weakness in Seoulin Bioscience Co.,Ltd.'s (KOSDAQ:038070) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?Seoulin BioscienceLtd (KOSDAQ:038070) has had a rough three months with its share price down 8.8%. However, the...
Is New 90 Day High Low • Mar 09New 90-day low: ₩12,000The company is down 12% from its price of ₩13,667 on 09 December 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 14% over the same period.
分析記事 • Feb 15Introducing Seoulin BioscienceLtd (KOSDAQ:038070), A Stock That Climbed 54% In The Last YearSeoulin Bioscience Co.,Ltd. ( KOSDAQ:038070 ) shareholders might be concerned after seeing the share price drop 11% in...
分析記事 • Jan 20Is Seoulin Bioscience Co.,Ltd. (KOSDAQ:038070) A Great Dividend Stock?Today we'll take a closer look at Seoulin Bioscience Co.,Ltd. ( KOSDAQ:038070 ) from a dividend investor's perspective...
Valuation Update With 7 Day Price Move • Jan 13Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₩14,900, the stock is trading at a trailing P/E ratio of 28.1x, down from the previous P/E ratio of 33.6x. This compares to an average P/E of 57x in the Biotechs industry in South Korea. Total returns to shareholders over the past three years are 40%.
Valuation Update With 7 Day Price Move • Jan 06Investor sentiment improved over the past weekAfter last week's 33% share price gain to ₩17,850, the stock is trading at a trailing P/E ratio of 33.6x, up from the previous P/E ratio of 25.3x. This compares to an average P/E of 58x in the Biotechs industry in South Korea. Total returns to shareholders over the past three years are 76%.
Is New 90 Day High Low • Jan 06New 90-day high: ₩17,850The company is up 48% from its price of ₩12,031 on 08 October 2020. The South Korean market is up 24% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 23% over the same period.
分析記事 • Dec 25Three Days Left Until Seoulin Bioscience Co.,Ltd. (KOSDAQ:038070) Trades Ex-DividendSome investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...
Upcoming Dividend • Dec 22Upcoming Dividend of ₩93.52 Per ShareWill be paid on the 17th of April to those who are registered shareholders by the 29th of December. The trailing yield of 0.7% is below the top quartile of South Korean dividend payers (2.6%), but it is higher than industry peers (0.3%).
Is New 90 Day High Low • Dec 14New 90-day high: ₩14,650The company is up 3.0% from its price of ₩14,250 on 15 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 6.0% over the same period.
分析記事 • Dec 06Is Seoulin Bioscience Co.,Ltd.'s (KOSDAQ:038070) Recent Stock Performance Influenced By Its Fundamentals In Any Way?Seoulin BioscienceLtd (KOSDAQ:038070) has had a great run on the share market with its stock up by a significant 10...
Valuation Update With 7 Day Price Move • Nov 10Market bids up stock over the past weekAfter last week's 17% share price gain to ₩13,750, the stock is trading at a trailing P/E ratio of 26.1x, up from the previous P/E ratio of 22.3x. This compares to an average P/E of 66x in the Biotechs industry in South Korea. Total returns to shareholders over the past three years are 28%.
Is New 90 Day High Low • Oct 23New 90-day low: ₩11,250The company is down 11% from its price of ₩12,700 on 24 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Biotechs industry, which is also down 11% over the same period.